verona
pharma
plc
operational
update
financial
results
three
nine
months
ended
september
london
stock
exchange
vrp
initiated
enhance
phase
clinical
trials
copd
completed
million
private
placement
commenced
pilot
clinical
study
patients
hospitalized
conference
call
today
edt
gmt
london
raleigh
globe
newswire
verona
pharma
plc
aim
vrp
nasdaq
vrna
verona
pharma
company
biopharmaceutical
company
focused
developing
commercializing
innovative
therapies
respiratory
diseases
announces
financial
results
three
nine
months
ended
september
provides
corporate
update
continue
make
outstanding
progress
delighted
started
four
clinical
trials
third
quarter
including
pivotal
ensifentrine
novel
inhaled
nebulized
copd
therapy
phase
studies
said
david
zaccardelli
pharm
president
chief
executive
officer
important
milestone
brings
us
closer
potentially
submitting
new
drug
application
ensifentrine
addressing
urgent
need
novel
therapy
treatment
chronic
obstructive
pulmonary
disease
copd
addition
two
enhance
clinical
trials
enrolled
patients
started
pilot
clinical
study
investigate
ensifentrine
delivered
via
pressurized
inhaler
pmdi
formulation
patients
hospitalized
clinical
data
prior
studies
ensifentrine
demonstrated
improves
lung
function
reduces
cellular
markers
inflammation
lungs
believe
ensifentrine
novel
mechanism
action
potential
benefit
patients
suffering
results
anticipated
first
half
also
third
quarter
initiated
second
multiple
dose
part
phase
study
pmdi
formulation
ensifentrine
copd
postponed
due
pandemic
results
expected
first
half
clinical
progress
supported
million
raise
completed
july
appreciate
highly
experienced
life
science
investors
participated
offering
funds
expected
support
operations
phase
clinical
programs
outlook
strategy
verona
pharma
aims
improve
health
quality
life
millions
people
affected
respiratory
diseases
company
development
candidate
ensifentrine
potential
provide
benefit
patients
suffering
respiratory
conditions
copd
cystic
fibrosis
cf
asthma
ensifentrine
novel
investigational
inhaled
therapy
shown
act
bronchodilator
agent
one
compound
initially
company
advancing
development
nebulized
ensifentrine
maintenance
treatment
copd
pleased
announce
verona
pharma
met
following
objectives
established
time
management
change
completing
meeting
fda
may
receive
guidance
design
phase
program
nebulized
ensifentrine
securing
million
gross
proceeds
million
net
commissions
expenses
private
placement
july
expect
sufficient
capital
fund
phase
program
nebulized
ensifentrine
initiating
enhance
phase
program
nebulized
ensifentrine
moderate
severe
copd
patients
september
operational
development
highlights
three
month
period
ended
september
financial
july
company
completed
million
private
placement
american
depositary
shares
adss
ordinary
shares
resulted
net
proceeds
approximately
million
giving
effect
transaction
related
fees
expenses
private
placement
company
expects
proceeds
private
placement
sufficient
support
operations
clinical
programs
september
verona
pharma
announced
plans
delist
aim
stock
market
effective
gmt
october
company
retain
listing
nasdaq
global
market
nasdaq
move
expected
enhance
liquidity
trading
combining
trading
transactions
nasdaq
reduce
costs
removing
duplicative
listing
compliance
fees
also
september
verona
pharma
rang
nasdaq
closing
bell
celebration
company
million
financing
third
quarter
company
changed
accounting
policy
regards
presentational
currency
presenting
financial
results
us
dollars
historical
results
including
six
months
ended
june
retrospectively
presented
us
dollars
clinical
july
company
received
notice
proceed
fda
investigational
new
drug
application
evaluate
pmdi
ensifentrine
randomized
pilot
clinical
study
treatment
patients
hospitalized
september
company
initiated
study
study
evaluate
effect
ensifentrine
key
outcomes
patients
hospitalized
including
facilitation
recovery
viral
infection
clinical
status
improvement
reduction
supplemental
oxygen
use
progression
mechanical
ventilation
august
company
initiated
second
multiple
dose
part
phase
study
evaluate
pmdi
ensifentrine
patients
moderate
severe
copd
results
expected
first
half
september
company
initiated
enhance
phase
trials
evaluate
efficacy
safety
nebulized
ensifentrine
patients
moderate
severe
copd
two
randomized
studies
evaluate
ensifentrine
monotherapy
added
onto
single
bronchodilator
study
enroll
approximately
moderate
severe
symptomatic
copd
patients
sites
primarily
europe
two
study
designs
replicate
measurements
efficacy
safety
data
weeks
also
evaluate
safety
patients
weeks
additionally
september
detailed
analysis
symptom
data
previously
reported
phase
clinical
trial
nebulized
ensifentrine
maintenance
treatment
copd
published
leading
peer
reviewed
journal
specialists
healthcare
professionals
international
journal
chronic
obstructive
pulmonary
disease
analyses
demonstrate
ensifentrine
meaningfully
improved
symptoms
quality
life
weeks
patients
moderate
severe
copd
also
september
tara
rheault
vice
president
r
global
project
management
presented
new
subgroup
analysis
phase
trials
nebulized
ensifentrine
copd
european
respiratory
society
international
congress
data
demonstrated
ensifentrine
monotherapy
added
onto
tiotropium
improved
lung
function
moderate
severe
copd
patients
regardless
smoking
status
history
chronic
bronchitis
weeks
financial
highlights
net
cash
cash
equivalents
short
term
investments
september
amounted
million
december
million
increase
due
completion
private
placement
gross
proceeds
approximately
million
net
proceeds
private
placement
approximately
million
deducting
placement
agent
fees
expenses
continue
evaluate
consider
financing
vehicles
including
venture
debt
facilities
potentially
provide
us
financial
flexibility
nine
months
ended
september
company
reported
operating
loss
million
nine
months
ended
september
million
reported
loss
tax
million
nine
months
ended
september
million
research
development
costs
fell
million
nine
months
ended
september
compared
prior
period
primarily
due
significantly
higher
costs
ongoing
phase
study
compared
start
costs
incurred
enhance
program
general
administrative
costs
increased
million
period
higher
costs
related
share
based
payment
charges
executive
changes
certain
costs
related
private
placement
recorded
expenses
statement
comprehensive
income
company
reported
loss
per
share
cents
nine
months
ended
september
nine
months
ended
september
cents
net
cash
used
operating
activities
nine
months
ended
september
million
nine
months
ended
september
million
cash
used
lower
predominantly
due
lower
cash
based
operating
costs
higher
cash
tax
credit
received
cash
generated
financing
activities
million
primarily
related
net
cash
proceeds
private
placement
nine
months
ended
september
company
assumed
contingent
liability
research
development
asset
light
determination
ensifentrine
moved
phase
phase
stage
clinical
development
future
cashflows
relating
potential
milestone
payment
potential
royalties
payable
remeasured
applying
updated
estimates
probabilities
success
based
assumed
reduced
clinical
risk
moving
phase
accordingly
company
recorded
increase
million
assumed
contingent
liability
corresponding
increase
related
research
development
intangible
asset
material
effect
current
period
comprehensive
loss
net
assets
cashflows
conference
call
webcast
information
verona
pharma
host
investment
community
conference
call
edt
gmt
thursday
october
discuss
financial
results
corporate
update
analysts
investors
may
participate
dialing
one
following
numbers
reference
conference
number
callers
united
states
international
callers
live
webcast
available
events
presentations
link
investors
page
company
website
audio
replay
available
days
electronic
copy
results
release
also
made
available
today
company
website
press
release
constitute
offer
sell
solicitation
offer
buy
company
securities
shall
constitute
offer
solicitation
sale
jurisdiction
offer
solicitation
sale
would
unlawful
prior
registration
qualification
securities
laws
jurisdiction
information
please
contact
verona
pharma
plc
tel
victoria
stewart
director
communications
info
singer
tel
nominated
adviser
uk
broker
aubrey
powell
george
tzimas
iqra
amin
corporate
finance
tom
salvesen
corporate
broking
optimum
strategic
communications
tel
european
media
investor
enquiries
verona
mary
clark
eva
haas
shabnam
bashir
argot
partners
tel
investor
enquiries
verona
kimberly
minarovich
michael
barron
impact
business
continuity
help
protect
health
safety
patients
caregivers
healthcare
professionals
involved
ongoing
clinical
trials
ensifentrine
well
employees
independent
contractors
company
continues
follow
guidance
fda
health
regulatory
authorities
regarding
conduct
clinical
trials
pandemic
ensure
safety
study
participants
minimize
risks
study
integrity
maintain
compliance
good
clinical
practice
gcp
company
continues
review
guidance
effect
pandemic
operations
clinical
trials
provide
update
becomes
aware
meaningful
disruption
caused
pandemic
clinical
trials
verona
pharma
closely
monitoring
activities
company
contract
manufacturers
associated
clinical
supply
ongoing
clinical
trials
satisfied
appropriate
plans
procedures
place
ensure
uninterrupted
future
supply
ensifentrine
clinical
trial
sites
subject
potential
limitations
operations
supply
chain
due
pandemic
company
continuing
monitor
situation
provide
update
becomes
aware
meaningful
disruption
caused
pandemic
clinical
supply
ensifentrine
clinical
trials
corporate
operations
financial
impact
verona
pharma
also
implemented
measures
help
keep
company
employees
families
local
communities
healthy
safe
employees
working
remotely
business
travel
restricted
pandemic
caused
significant
disruption
financial
markets
verona
pharma
successfully
raised
sufficient
capital
fund
phase
program
nebulized
ensifentrine
risk
factor
verona
pharma
assessed
potential
impact
business
pandemic
updated
risk
factor
disclosures
report
form
filed
sec
april
verona
pharma
plc
verona
pharma
biopharmaceutical
company
focused
developing
commercializing
innovative
therapies
treatment
respiratory
diseases
significant
unmet
medical
needs
successfully
developed
approved
verona
pharma
product
candidate
ensifentrine
potential
first
therapy
treatment
respiratory
diseases
combines
bronchodilator
activities
one
compound
company
evaluating
nebulized
ensifentrine
phase
clinical
program
enhance
ensifentrine
novel
inhaled
nebulized
copd
therapy
copd
maintenance
treatment
company
raised
gross
proceeds
million
private
placement
july
expects
funds
support
operations
phase
clinical
program
two
additional
formulations
ensifentrine
currently
phase
development
treatment
copd
dry
powder
inhaler
dpi
pressurized
inhaler
pmdi
ensifentrine
evaluated
pilot
clinical
study
patients
hospitalized
potential
applications
cystic
fibrosis
asthma
respiratory
diseases
information
please
visit
forward
looking
statements
press
release
operational
review
outlook
financial
review
contain
statements
statements
contained
press
release
respect
operational
review
outlook
financial
review
relate
matters
historical
fact
considered
statements
including
limited
statements
regarding
development
potential
ensifentrine
including
potential
help
patients
recover
initiation
progress
timing
clinical
trials
related
data
readouts
expectations
surrounding
clinical
trial
results
responses
fda
market
opportunity
various
formulations
ensifentrine
including
estimates
market
size
copd
impact
pandemic
business
operations
company
future
financial
results
sufficiency
cash
cash
equivalents
expectations
surrounding
additional
funding
statements
based
management
current
expectations
statements
neither
promises
guarantees
involve
known
unknown
risks
uncertainties
important
factors
may
cause
actual
results
performance
achievements
materially
different
expectations
expressed
implied
statements
including
limited
following
limited
operating
history
need
additional
funding
complete
development
commercialization
ensifentrine
may
available
may
force
us
delay
reduce
eliminate
development
commercialization
efforts
reliance
business
success
ensifentrine
product
candidate
development
economic
political
regulatory
risks
involved
international
operations
lengthy
expensive
process
clinical
drug
development
uncertain
outcome
serious
adverse
undesirable
unacceptable
side
effects
associated
ensifentrine
could
adversely
affect
ability
develop
commercialize
ensifentrine
potential
delays
enrolling
patients
could
adversely
affect
research
development
efforts
may
successful
developing
ensifentrine
multiple
indications
ability
obtain
approval
commercialize
ensifentrine
multiple
major
pharmaceutical
markets
misconduct
improper
activities
employees
consultants
principal
investigators
service
providers
loss
key
personnel
ability
recruit
replacement
personnel
well
impact
management
team
transition
material
differences
data
final
data
reliance
third
parties
including
clinical
investigators
manufacturers
suppliers
risks
related
parties
ability
successfully
develop
commercialize
ensifentrine
lawsuits
related
patents
covering
ensifentrine
potential
patents
found
invalid
unenforceable
impact
pandemic
operations
continuity
business
general
economic
conditions
vulnerability
natural
disasters
global
economic
factors
unexpected
events
including
health
epidemics
pandemics
like
important
factors
caption
risk
factors
registration
statement
form
filed
sec
august
reports
filed
sec
could
cause
actual
results
differ
materially
indicated
statements
made
press
release
operational
review
outlook
financial
review
statements
represent
management
estimates
date
press
release
operational
financial
review
may
elect
update
statements
point
future
disclaim
obligation
even
subsequent
events
cause
views
change
statements
relied
upon
representing
views
date
subsequent
date
press
release
operational
review
outlook
financial
review
announcement
contains
inside
information
purposes
article
regulation
eu
operational
review
company
overview
verona
pharma
focused
developing
commercializing
phase
candidate
ensifentrine
treatment
significant
unmet
respiratory
needs
chronic
obstructive
pulmonary
disease
copd
ensifentrine
novel
mechanism
action
potential
first
therapy
treatment
respiratory
diseases
combines
bronchodilator
activities
one
compound
well
copd
ensifentrine
potential
applications
cystic
fibrosis
asthma
respiratory
diseases
verona
pharma
evaluating
nebulized
ensifentrine
phase
clinical
program
enhance
ensifentrine
novel
inhaled
nebulized
copd
therapy
maintenance
treatment
copd
company
raised
gross
proceeds
million
private
placement
july
expects
funds
support
operations
phase
clinical
program
two
additional
formulations
ensifentrine
currently
phase
development
treatment
copd
dry
powder
inhaler
dpi
pressurized
inhaler
pmdi
ensifentrine
evaluated
pilot
clinical
study
patients
hospitalized
ensifentrine
demonstrated
significant
clinically
meaningful
improvements
lung
function
copd
symptoms
including
breathlessness
patients
moderate
severe
copd
addition
ensifentrine
showed
improved
lung
function
reduced
lung
volumes
patients
taking
standard
bronchodilator
therapy
including
maximum
bronchodilator
treatment
dual
triple
therapy
ensifentrine
well
tolerated
clinical
trials
involving
people
date
ensifentrine
highlights
dual
bronchodilator
agent
single
molecule
potentially
first
novel
class
bronchodilator
copd
years
potentially
bronchodilator
option
existing
dual
triple
therapy
copd
common
progressive
respiratory
disease
without
cure
damages
airways
lungs
leading
debilitating
breathlessness
hospitalizations
death
copd
major
impact
everyday
life
patients
struggle
basic
activities
getting
bed
showering
walking
copd
affects
approximately
million
people
worldwide
third
leading
cause
death
globally
according
world
health
organization
copd
patients
frequently
treated
bronchodilators
relieve
airway
constriction
make
easier
breathe
corticosteroids
reduce
lung
inflammation
despite
receiving
maximum
therapy
many
patients
million
alone
remain
symptomatic
urgently
need
additional
treatment
believe
ensifentrine
provide
significant
benefits
patients
pharmacological
profile
ensifentrine
including
novel
mechanism
action
complementary
existing
classes
strong
improvement
copd
symptoms
meaningful
improvement
quality
life
addresses
large
unmet
need
experienced
copd
patients
today
ensifentrine
dual
phosphodiesterase
pde
inhibitor
delivered
via
inhalation
locally
lung
maximize
pulmonary
exposure
ensifentrine
minimizing
systemic
exposure
minimizes
gastrointestinal
disturbance
associated
oral
inhibitors
cardiovascular
seen
oral
inhibitors
nebulized
formulation
ensifentrine
used
adults
age
dexterity
regardless
peak
inspiratory
flow
offering
advantages
patients
may
struggle
operate
handheld
inhaler
devices
low
peak
inspiratory
flow
nevertheless
handheld
inhaler
formats
also
important
delivery
mechanisms
approximately
billion
market
maintenance
copd
therapies
verona
pharma
developed
formulations
ensifentrine
dpi
pmdi
formats
successfully
demonstrated
proof
concept
copd
patients
formulations
development
pmdi
dpi
formulations
ensifentrine
provides
expanded
opportunities
life
cycle
management
including
new
indications
formulation
combinations
collaborations
verona
pharma
sees
initial
market
opportunity
company
intends
commercialize
nebulized
ensifentrine
market
outside
verona
pharma
intends
identify
collaborators
maximize
ensifentrine
potential
regions
financial
review
financial
review
nine
three
month
periods
ended
september
nine
months
ended
september
research
development
costs
research
development
costs
million
nine
months
ended
september
compared
million
nine
months
ended
september
decrease
million
predominantly
attributable
million
decrease
clinical
trial
expenses
partially
offset
million
increase
share
based
payment
charges
six
clinical
trials
ongoing
preparation
closing
nine
months
ended
september
compared
four
period
costs
related
phase
clinical
study
ensifentrine
added
tiotropium
period
significantly
higher
costs
enhance
program
incurred
period
general
administrative
costs
general
administrative
costs
million
nine
months
ended
september
compared
million
nine
months
ended
september
increase
million
increase
included
million
costs
relating
executive
changes
relocation
office
north
carolina
million
higher
director
officers
liability
insurance
costs
million
costs
relating
private
placement
million
increase
share
based
payment
charges
costs
increased
million
finance
income
expense
finance
income
expense
driven
changes
fair
value
warrant
liability
changes
present
value
assumed
contingent
liability
foreign
exchange
movements
cash
cash
equivalents
interest
income
expense
finance
income
million
nine
months
ended
september
million
nine
months
ended
september
finance
income
lower
nine
months
ended
september
fair
value
warrant
liability
decreased
million
period
compared
increase
nine
months
ended
september
increase
period
recorded
finance
expense
gains
cash
short
term
investments
due
foreign
exchange
movements
million
nine
months
ended
september
compared
million
period
prior
year
interest
received
cash
short
term
investments
reduced
million
due
lower
overall
interest
rates
change
investment
policy
use
government
debt
money
market
funds
compared
term
deposits
previously
utilized
finance
expense
million
nine
months
ended
september
compared
million
nine
months
ended
september
increase
nine
months
ended
september
primarily
related
million
accounting
charge
relating
unwind
discount
assumed
contingent
liability
present
value
contingent
liability
increases
estimated
time
potential
payment
becoming
closer
additionally
million
charge
relating
increase
fair
value
warrant
liability
nine
months
ended
september
prior
period
present
value
warrant
liability
decreased
resulting
finance
income
taxation
tax
credit
statement
comprehensive
income
predominantly
made
uk
tax
credit
small
tax
charge
relating
us
operations
uk
tax
credits
calculated
percentage
qualifying
research
development
expenditure
payable
cash
uk
government
company
credits
recorded
financial
year
expected
received
financial
year
expect
magnitude
credits
increase
expenditures
phase
program
accelerate
continue
significant
element
financing
strategy
tax
credit
nine
month
period
ended
september
million
compared
credit
million
nine
months
ended
september
decrease
million
decrease
credit
amount
attributable
decreased
expenditures
research
development
compared
period
assumed
contingent
liability
research
development
asset
second
quarter
company
contingent
liability
research
development
asset
light
determination
ensifentrine
moved
phase
phase
stage
clinical
development
future
cashflows
relating
milestone
payment
potential
royalties
payable
remeasured
applying
estimated
probabilities
success
assumed
contingent
liability
relates
potential
future
cashflows
adjusted
accordingly
company
recorded
increase
million
contingent
liability
corresponding
increase
related
research
development
asset
material
effect
current
period
comprehensive
loss
net
assets
cashflows
discount
used
calculate
present
value
assumed
contingent
liability
unwinds
quarter
time
potential
payment
becomes
closer
recorded
finance
expense
private
placement
july
verona
pharma
announced
raised
approximately
million
private
placement
new
existing
institutional
accredited
investors
private
placement
comprised
placement
adss
representing
eight
ordinary
shares
ordinary
shares
company
price
per
ads
company
ordinary
shares
equivalent
price
per
ordinary
share
net
proceeds
private
placement
approximately
million
deducting
placement
agent
fees
associated
expenses
including
costs
recorded
equity
statement
comprehensive
income
million
costs
paid
october
company
need
raise
additional
capital
future
assurance
able
acceptable
terms
cash
flows
net
cash
used
operating
activities
decreased
million
nine
months
ended
september
million
nine
months
ended
september
fall
million
operating
loss
nine
months
ended
september
million
higher
included
million
higher
share
based
payment
charges
cash
related
charges
approximately
million
lower
addition
cash
tax
credit
million
received
million
higher
nine
months
ended
september
offsetting
timing
supplier
payments
led
million
higher
cash
outflow
current
period
decrease
net
cash
generated
investing
activities
million
nine
months
ended
september
million
nine
months
ended
september
due
net
movement
funds
short
term
investments
cash
less
period
million
increase
cash
generated
financing
activities
primarily
due
net
cash
received
private
placement
cash
cash
equivalents
investments
net
cash
cash
equivalents
investments
september
increased
million
million
december
due
net
receipts
private
placement
partially
offset
utilization
cash
ordinary
operating
activities
net
assets
net
assets
increased
million
september
million
december
predominantly
due
increase
equity
private
placement
partially
offset
company
operating
activities
three
months
ended
september
operating
loss
three
months
ended
september
million
september
million
loss
tax
three
months
ended
september
million
september
million
research
development
costs
research
development
costs
million
three
months
ended
september
compared
million
three
months
ended
september
decrease
million
decrease
primarily
attributable
million
decrease
clinical
trial
expenses
partially
offset
million
increase
share
based
payment
charge
recorded
three
months
ended
september
costs
relating
four
clinical
trials
ongoing
preparation
closing
three
months
ended
september
compared
two
comparative
period
however
costs
related
phase
clinical
study
ensifentrine
added
tiotropium
period
significantly
higher
costs
enhance
program
incurred
period
general
administrative
costs
general
administrative
costs
million
three
months
ended
september
compared
million
three
months
ended
september
increase
million
increase
attributable
million
costs
related
private
placement
recorded
expenses
million
increase
directors
officers
liability
insurance
costs
million
increase
share
based
payment
charges
finance
income
expense
finance
income
million
three
months
ended
september
million
three
months
ended
september
finance
income
three
months
ended
september
predominantly
comprised
million
foreign
exchange
gain
cash
cash
equivalents
broadly
similar
gain
prior
period
also
prior
period
included
million
relating
movements
fair
value
warrants
recorded
finance
expense
period
million
interest
cash
balances
finance
expense
million
three
months
ended
september
compared
thousand
three
months
ended
september
increase
primarily
due
million
charge
relating
revaluation
warrants
million
charge
relating
unwind
discount
assumed
contingent
liability
period
taxation
taxation
three
months
ended
september
amounted
credit
million
compared
credit
million
three
months
ended
september
verona
pharma
plc
condensed
consolidated
interim
statements
financial
position
unaudited
september
december
january
restated
restated
notes
september
december
january
assets
assets
goodwill
intangible
assets
property
plant
equipment
asset
total
assets
current
assets
prepayments
receivables
current
tax
receivable
short
term
investments
cash
cash
equivalents
total
current
assets
total
assets
equity
liabilities
capital
reserves
attributable
equity
holders
share
capital
share
premium
payment
reserve
cumulative
translation
adjustment
accumulated
loss
total
equity
current
liabilities
derivative
financial
instrument
lease
liabilities
trade
payables
total
current
liabilities
liabilities
assumed
contingent
liability
lease
liability
deferred
income
total
liabilities
total
equity
liabilities
accompanying
notes
form
integral
part
condensed
consolidated
financial
statements
comparative
results
restated
reflect
change
presentational
currency
see
note
verona
pharma
plc
condensed
consolidated
interim
statements
comprehensive
income
three
nine
months
ended
september
september
unaudited
restated
restated
restated
notes
three
months
ended
september
three
months
ended
september
nine
months
ended
september
nine
months
ended
september
research
development
costs
general
administrative
costs
operating
loss
finance
income
finance
expense
loss
taxation
taxation
credit
loss
period
comprehensive
loss
items
might
subsequently
reclassified
profit
loss
exchange
differences
translation
presentational
currency
total
comprehensive
loss
attributable
owners
company
loss
per
ordinary
share
basic
diluted
cents
accompanying
notes
form
integral
part
condensed
consolidated
financial
statements
comparative
results
restated
reflect
change
presentational
currency
see
note
verona
pharma
plc
condensed
consolidated
interim
statements
changes
equity
three
months
ended
september
september
unaudited
restated
restated
restated
restated
restated
restated
share
capital
share
premium
expenses
cumulative
translation
adjustment
cta
accumulated
loss
total
equity
retranslated
balances
july
impact
cta
reserve
change
presentation
currency
us
dollars
adjusted
balance
july
loss
period
comprehensive
income
year
exchange
differences
translation
presentational
currency
total
comprehensive
loss
period
payments
balance
september
balance
july
loss
period
total
comprehensive
loss
period
new
share
capital
issued
private
placement
transaction
costs
share
capital
issued
share
options
exercised
period
payments
balance
september
thousand
relates
reversal
previous
cumulative
translation
adjustments
previously
recorded
accumulated
loss
shown
separately
relating
translation
verona
pharma
results
us
dollars
pounds
sterling
recording
cumulative
translation
adjustments
relating
translation
verona
pharma
plc
results
pounds
sterling
us
dollars
result
change
presentational
currency
see
note
information
comparative
results
restated
reflect
change
presentational
currency
see
note
verona
pharma
plc
condensed
consolidated
interim
statements
changes
equity
nine
months
ended
september
september
unaudited
restated
restated
restated
restated
restated
restated
share
capital
share
premium
expenses
cumulative
translation
adjustment
cta
accumulated
loss
total
equity
retranslated
balances
january
impact
adoption
ifrs
impact
cta
reserve
change
presentation
currency
us
dollars
adjusted
balance
january
loss
period
comprehensive
income
year
exchange
differences
translation
presentational
currency
total
comprehensive
loss
period
payments
balance
september
balance
january
loss
period
comprehensive
loss
year
exchange
differences
translation
presentational
currency
total
comprehensive
loss
period
new
share
capital
issued
private
placement
transaction
costs
share
capital
issued
share
options
exercised
period
payments
balance
september
thousand
relates
adoption
ifrs
see
note
thousand
relates
reversal
previous
cumulative
translation
adjustments
previously
recorded
accumulated
loss
shown
separately
relating
translation
verona
pharma
results
us
dollars
pounds
sterling
recording
cumulative
translation
adjustments
relating
translation
verona
pharma
plc
results
pounds
sterling
us
dollars
result
change
presentational
currency
see
note
information
comparative
results
restated
reflect
change
presentational
currency
see
note
verona
pharma
plc
condensed
consolidated
interim
statements
cash
flows
nine
months
ended
september
september
unaudited
restated
nine
months
ended
september
nine
months
ended
september
cash
used
operating
activities
loss
taxation
finance
income
finance
expense
payment
charge
increase
prepayments
receivables
increase
trade
payables
depreciation
property
plant
equipment
right
use
asset
impairment
right
use
asset
unrealized
foreign
exchange
gains
losses
amortization
intangible
assets
cash
used
operating
activities
cash
inflow
taxation
net
cash
used
operating
activities
cash
flow
investing
activities
interest
received
purchase
plant
equipment
payment
patents
computer
software
transfer
short
term
investments
maturity
short
term
investments
net
cash
generated
investing
activities
cash
flow
financing
activities
proceeds
private
placement
transaction
costs
private
placement
payment
lease
liabilities
net
cash
generated
used
financing
activities
net
increase
cash
cash
equivalents
cash
cash
equivalents
beginning
period
effect
exchange
rates
cash
cash
equivalents
cash
cash
equivalents
end
period
comparative
results
restated
reflect
change
presentational
currency
see
note
verona
pharma
plc
notes
condensed
consolidated
interim
financial
statements
nine
months
ended
september
general
information
verona
pharma
plc
company
subsidiaries
biopharmaceutical
company
focused
developing
commercializing
innovative
therapeutics
treatment
respiratory
diseases
significant
unmet
medical
needs
company
public
limited
company
currently
dual
listed
ordinary
shares
listed
aim
market
operated
london
stock
exchange
american
depositary
shares
adss
nasdaq
global
market
nasdaq
company
incorporated
domiciled
united
kingdom
address
registered
office
central
square
cardiff
united
kingdom
company
two
subsidiaries
verona
pharma
rhinopharma
limited
rhinopharma
wholly
owned
september
verona
pharma
announced
plans
delist
aim
stock
market
effective
october
company
retain
listing
nasdaq
basis
accounting
unaudited
condensed
consolidated
interim
financial
statements
verona
pharma
plc
subsidiaries
verona
pharma
rhinopharma
limited
together
group
nine
months
ended
september
include
statements
required
full
annual
financial
statements
read
conjunction
consolidated
financial
statements
group
december
accounts
company
auditors
delivered
unqualified
audit
report
delivered
registrar
companies
period
company
functional
currency
changed
pounds
sterling
us
dollars
consequence
group
changed
accounting
policy
present
financial
statements
us
dollars
see
note
changes
accounting
policies
contained
annual
consolidated
financial
statements
year
ended
december
prepared
accordance
international
financial
reporting
standards
ifrs
issued
international
accounting
standards
board
adopted
eu
unaudited
condensed
interim
financial
statements
authorized
issue
company
board
directors
october
group
activities
results
exposed
seasonality
group
operates
single
operating
reportable
segment
going
concern
group
incurred
recurring
losses
since
inception
including
net
losses
million
million
million
years
ended
december
respectively
addition
september
group
accumulated
loss
million
group
expects
continue
generate
operating
losses
foreseeable
future
july
group
announced
raised
million
private
placement
private
placement
net
proceeds
transaction
related
fees
expenses
approximately
million
see
note
issuance
date
condensed
consolidated
interim
financial
statements
group
therefore
expects
cash
cash
equivalents
sufficient
fund
operating
expenses
capital
expenditure
requirements
least
twelve
months
issuance
date
condensed
consolidated
interim
financial
statements
accordingly
consolidated
financial
statements
prepared
basis
assumes
group
continue
going
concern
contemplates
realization
assets
satisfaction
liabilities
commitments
ordinary
course
business
impairment
intangible
assets
goodwill
assets
group
continues
review
effect
pandemic
operations
ongoing
planned
clinical
trials
potential
disruption
financial
markets
management
determined
current
effect
group
require
impairment
intangible
assets
goodwill
company
market
value
still
supports
value
assets
however
management
continue
monitor
situation
triggering
events
relate
pandemic
issues
dividend
directors
recommend
payment
dividend
nine
months
ended
september
nine
months
ended
september
nil
year
ended
december
nil
change
presentational
functional
currency
accounting
policy
change
change
presentational
currency
july
group
changed
presentational
currency
pounds
sterling
us
dollars
change
made
retrospectively
comparative
financial
statements
including
six
months
june
restated
using
following
procedures
assets
liabilities
translated
us
dollars
closing
rate
exchange
income
expenses
translated
us
dollars
average
rate
month
recorded
approximates
rate
date
transactions
equity
balances
translated
historical
rates
date
transactions
translation
differences
taken
cumulative
translation
adjustment
reserve
statements
cash
flows
prepared
functional
currency
entities
translated
presentational
currency
rates
approximating
dates
transactions
accordance
ias
presentation
financial
statements
transition
balance
sheet
included
primary
financial
statements
change
functional
currency
functional
currency
entity
defined
ias
effects
changes
foreign
exchange
rates
currency
primary
economic
environment
entity
operates
determining
point
functional
currency
changes
matter
judgment
economic
activity
changes
time
six
months
june
management
changes
resulted
lower
people
costs
paid
pounds
sterling
following
private
placement
company
entered
contracts
commence
phase
trials
ensifentrine
majority
costs
incurred
us
dollars
management
reviewed
budgeted
activities
next
five
years
identified
majority
costs
second
half
onwards
incurred
us
dollars
furthermore
private
placement
july
raised
funds
us
dollars
delisting
aim
future
fund
raises
us
dollars
also
commercial
focus
company
us
market
consequence
management
determined
company
functional
currency
changed
sterling
us
dollars
accounted
prospectively
july
convert
company
books
records
us
dollars
assets
liabilities
translated
closing
rate
exchange
june
segmental
reporting
group
activities
covered
one
operating
reporting
segment
drug
development
changes
management
assessment
operating
reporting
segment
group
period
assets
based
united
kingdom
apart
asset
relating
property
lease
associated
fixtures
fittings
united
states
financial
instruments
group
activities
expose
variety
financial
risks
market
risk
including
foreign
currency
risk
cash
flow
fair
value
interest
rate
risk
credit
risk
liquidity
risk
condensed
consolidated
interim
financial
statements
include
financial
risk
management
information
disclosures
required
annual
financial
statements
read
conjunction
group
annual
financial
statements
year
ended
december
addition
due
change
company
functional
currency
us
dollars
private
placement
foreign
exchange
risk
profile
group
changed
discussed
currency
risk
foreign
currency
risk
reflects
risk
company
net
assets
negatively
impacted
due
fluctuations
exchange
rates
company
entered
foreign
exchange
contracts
hedge
gains
losses
foreign
exchange
fluctuations
june
movements
value
us
dollar
balances
impacted
net
assets
july
movements
value
pounds
sterling
balances
impact
net
assets
summary
data
company
exposure
currency
risk
follows
figures
us
dollar
values
balances
currency
september
usd
gbp
eur
cash
cash
equivalents
trade
payables
sterling
element
assumed
contingent
liability
sensitivity
analysis
reasonably
possible
strengthening
weakening
euro
pounds
sterling
us
dollars
september
would
affected
measurement
financial
instruments
denominated
foreign
currency
following
table
shows
movement
currency
would
give
rise
profit
loss
corresponding
entry
equity
profit
loss
equity
strengthening
weakening
september
gbp
movement
eur
movement
foreign
currency
denominated
trade
payables
short
term
nature
generally
days
except
sterling
element
assumed
contingent
liability
likely
become
due
two
five
years
balance
sheet
date
critical
estimates
judgements
preparation
condensed
consolidated
interim
financial
statements
require
management
make
judgments
estimates
assumptions
affect
application
accounting
policies
reported
amounts
assets
liabilities
income
expenses
actual
results
may
differ
estimates
preparing
condensed
consolidated
interim
financial
statements
significant
judgments
made
management
applying
group
accounting
policies
key
sources
estimation
uncertainty
applied
consolidated
financial
statements
year
ended
december
exception
development
pandemic
judgment
required
determining
date
company
functional
currency
changed
see
note
assessed
whether
pandemic
impact
key
estimates
judgments
previously
reported
respect
derivative
financial
instrument
assumed
contingent
liability
balances
concluded
significant
impact
finance
income
expense
restated
restated
three
months
ended
september
three
months
ended
september
nine
months
ended
september
nine
months
ended
september
finance
income
interest
received
cash
short
term
investments
foreign
exchange
gain
translating
foreign
currency
denominated
cash
balances
fair
value
adjustment
derivative
financial
instruments
note
total
finance
income
restated
restated
three
months
ended
september
three
months
ended
september
nine
months
ended
september
nine
months
ended
september
finance
expense
fair
value
adjustment
derivative
financial
instruments
note
interest
discounted
lease
liability
unwinding
discount
factor
movements
related
assumed
contingent
liability
note
total
finance
expense
taxation
tax
credit
nine
month
period
ended
september
amounts
million
primarily
consists
estimated
research
development
tax
credit
receivable
qualifying
expenditure
incurred
nine
month
period
ended
september
amount
million
less
tax
expense
million
related
operations
nine
month
period
ended
september
million
tax
credit
comprising
million
research
development
tax
credit
less
thousand
expense
tax
operations
tax
credit
three
month
period
ended
september
amounts
million
consists
estimated
research
development
tax
credit
receivable
qualifying
expenditure
incurred
three
month
period
ended
september
amount
million
less
tax
expense
thousand
related
operations
three
month
period
ended
september
million
tax
credit
comprising
million
research
development
tax
credit
less
thousand
expense
tax
operations
loss
per
share
calculation
nine
months
ended
september
basic
loss
per
share
cents
september
cents
calculated
dividing
loss
nine
months
ended
september
weighted
average
number
ordinary
shares
issue
nine
months
ended
september
september
potential
ordinary
shares
treated
dilutive
entity
incurring
losses
shares
would
three
months
ended
september
basic
loss
per
share
cents
september
cents
calculated
dividing
loss
three
months
ended
september
weighted
average
number
ordinary
shares
issue
three
months
ended
september
september
potential
ordinary
shares
treated
dilutive
entity
incurring
losses
shares
would
ads
represents
ordinary
shares
company
profit
loss
per
ads
period
equal
eight
times
profit
loss
per
share
intangible
assets
restated
restated
restated
restated
ip
r
computer
software
patents
total
cost
january
additions
translation
differences
recognized
comprehensive
loss
september
accumulated
amortization
january
charge
period
translation
differences
recognized
comprehensive
loss
september
net
book
value
september
movements
assumed
contingent
liability
see
note
relate
changes
estimated
cashflows
probabilities
success
recognized
additions
research
development
ip
r
asset
relates
nine
months
ended
september
group
determined
moved
phase
ensifentrine
clinical
development
plan
phase
probability
success
estimated
cashflows
changed
million
movement
liability
relating
recorded
addition
ip
r
asset
relates
changes
estimated
cashflows
probabilities
success
assets
nine
months
ended
september
office
lease
signed
north
carolina
liability
corresponding
rou
asset
thousand
recorded
lease
terminates
april
december
group
rou
asset
relating
office
space
new
york
nine
months
ended
september
new
york
office
closed
rou
asset
subject
impairment
review
net
book
value
thousand
subsequently
expensed
income
statement
group
retains
liability
thousand
relating
asset
short
term
investments
short
term
investments
september
amounted
total
nil
december
million
consisted
fixed
term
deposits
cash
cash
equivalents
included
cash
cash
equivalents
cash
balances
held
bank
term
deposits
maturities
less
three
months
inception
investments
money
market
funds
money
market
funds
classified
cash
cash
equivalents
low
risk
instruments
readily
convertible
known
amount
cash
subject
insignificant
risk
change
value
management
intention
manage
funds
cash
use
meet
short
term
cash
requirements
derivative
financial
instrument
july
company
issued
warrants
allowing
holders
subscribe
ordinary
share
per
share
exercise
price
warrants
exercised
may
warrant
holders
opt
cashless
exercise
warrants
whereby
choose
exchange
warrants
held
reduced
number
warrants
exercisable
nil
consideration
reduced
number
warrants
calculated
based
formula
considering
share
price
exercise
price
warrants
warrants
therefore
classified
derivative
financial
liability
since
exercise
could
result
variable
number
shares
issued
september
december
warrants
shares
effect
september
december
shares
available
issued
warrants
exercise
price
interest
rate
remaining
term
exercise
years
years
annualized
volatility
dividend
rate
september
group
updated
underlying
assumptions
calculated
fair
value
warrants
million
variance
nine
month
period
ended
september
million
nine
month
period
ended
september
million
recorded
finance
income
expense
consolidated
statement
comprehensive
income
restated
derivative
financial
instrument
derivative
financial
instrument
january
fair
value
adjustments
recognized
profit
loss
foreign
exchange
differences
recognized
loss
period
translation
differences
recognized
comprehensive
loss
september
amount
recognized
september
effect
volatility
deviate
presented
following
table
volatility
pts
variable
base
case
reported
fair
value
variable
assumed
contingent
liability
related
business
combination
value
assumed
contingent
liability
september
amounted
million
december
million
increase
value
assumed
contingent
liability
nine
months
ended
september
amounted
million
nine
months
ended
september
thousand
assumed
contingent
liability
relates
acquisition
rights
certain
patents
patent
applications
relating
ensifentrine
related
compounds
company
obliged
pay
royalties
ligand
assumed
contingent
liability
accounted
liability
value
measured
amortized
cost
using
effective
interest
rate
method
changes
estimated
cash
flows
probability
success
changes
expected
cash
flows
based
estimated
future
royalties
payable
derived
sales
forecasts
assessment
probability
success
using
standard
market
probabilities
respiratory
drug
development
value
assumed
contingent
arrangement
discounted
back
net
present
value
applying
effective
interest
rate
relating
changes
estimated
cash
flows
probabilities
success
recognized
ip
r
asset
relates
unwinding
liability
recorded
finance
expense
may
group
determined
moved
phase
ensifentrine
clinical
development
plan
phase
consequence
probability
success
changed
reducing
adjustment
applied
estimated
cashflows
furthermore
group
carried
market
research
updated
forecasts
ensifentrine
revenue
maintenance
treatment
chronic
obstructive
pulmonary
disorder
using
nebulized
formulation
group
therefore
updated
estimated
cashflows
second
quarter
third
quarter
events
triggered
remeasurement
restated
january
contingent
liability
foreign
exchange
differences
recognized
loss
period
translation
differences
recognized
comprehensive
loss
unwinding
discount
factor
september
material
difference
fair
value
carrying
value
financial
liability
amount
recognized
september
million
effect
underlying
assumptions
deviate
presented
following
table
assuming
variables
change
probability
success
pt
revenue
variable
base
case
reported
fair
value
variable
share
option
plans
nine
months
ended
september
company
granted
total
share
options
restricted
stock
units
rsus
nine
months
ended
september
company
granted
share
options
rsus
movement
number
company
share
options
set
relate
options
ordinary
shares
restated
weighted
average
exercise
price
weighted
average
exercise
price
outstanding
january
granted
period
expired
period
forfeited
period
outstanding
options
september
movement
number
company
rsus
set
relate
rsus
ordinary
shares
outstanding
january
granted
period
exercised
period
forfeited
period
outstanding
rsus
september
rsus
issued
related
element
annual
base
salary
related
additional
equity
grants
zaccardelli
hahn
see
note
using
valuation
model
fair
value
rsus
relating
annual
base
salary
fair
value
rsu
relating
additional
grants
payment
expense
nine
months
ended
september
million
nine
months
ended
september
million
related
party
transactions
directors
officers
authority
responsibility
planning
directing
controlling
activities
company
therefore
comprise
key
management
personnel
defined
ias
related
party
disclosures
nine
months
ended
september
karlsson
company
former
ceo
piers
morgan
company
former
cfo
resigned
replaced
david
zaccardelli
ceo
president
mark
hahn
cfo
karlsson
severance
agreement
included
severance
pay
equal
cash
bonus
payment
compensation
termination
employment
base
salary
lieu
notice
benefits
included
continued
medical
life
insurance
continued
pension
contributions
february
piers
morgan
severance
agreement
included
severance
pay
equal
payment
lieu
notice
cash
bonus
ex
gratia
compensation
additional
compensation
termination
employment
pursuant
terms
employment
agreement
zaccardelli
entitled
receive
annual
base
salary
payable
cash
restricted
stock
units
target
annual
bonus
opportunity
annual
base
salary
zaccardelli
also
entitled
receive
award
restricted
stock
units
equal
company
outstanding
ordinary
shares
additional
award
restricted
stock
units
company
raises
additional
equity
capital
fiscal
year
intended
result
zaccardelli
equity
awards
portion
base
salary
payable
restricted
stock
units
equal
company
outstanding
ordinary
shares
applicable
date
issuance
following
private
placement
july
zaccardelli
received
additional
award
see
note
pursuant
terms
employment
agreement
hahn
entitled
receive
annual
base
salary
payable
cash
restricted
stock
units
target
annual
bonus
opportunity
annual
base
salary
hahn
also
entitled
receive
initial
award
restricted
stock
units
equal
company
outstanding
ordinary
shares
award
restricted
stock
units
equal
company
outstanding
ordinary
shares
six
months
employment
also
entitled
additional
award
restricted
stock
units
company
raises
additional
equity
capital
fiscal
year
intended
result
hahn
equity
awards
portion
base
salary
payable
restricted
stock
units
equal
company
outstanding
ordinary
shares
applicable
date
issuance
following
private
placement
july
hahn
received
additional
award
see
note
nine
months
ended
september
rsus
issued
zaccardelli
hahn
respectively
vested
shares
issued
may
august
pursuant
employment
agreements
nine
months
ended
september
zaccardelli
hahn
awarded
aggregate
rsus
equal
company
outstanding
ordinary
shares
july
nine
months
ended
september
board
directors
awarded
rsus
share
options
ebsworth
cunningham
edwards
shah
sinha
ullman
awarded
rsus
gupta
sinclair
awarded
share
options
connection
private
placement
certain
directors
officer
company
participating
directors
officer
subscribed
new
ordinary
shares
price
adss
price
summary
participating
directors
officers
shown
name
title
amount
number
shares
ebsworth
chairman
zaccardelli
president
ceo
sinha
connected
persons
director
ullman
director
edwards
director
hahn
cfo
july
novo
holdings
vivo
capital
held
approximately
per
cent
per
cent
respectively
verona
pharma
issued
ordinary
share
capital
considered
related
party
company
defined
aim
rules
companies
participation
novo
holdings
vivo
capital
financing
deemed
constitute
related
party
transaction
pursuant
aim
rule
post
closing
financing
july
novo
holdings
vivo
capital
longer
related
parties
july
private
placement
july
verona
pharma
announced
raised
approximately
million
private
placement
new
existing
institutional
accredited
investors
private
placement
private
placement
comprised
private
placement
adss
representing
eight
ordinary
shares
ordinary
shares
price
per
ads
ordinary
shares
equivalent
price
per
ordinary
share
net
proceeds
financing
approximately
million
deducting
placement
agent
fees
estimated
expenses
post
balance
sheet
events
post
balance
sheet
events
report
